This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China.View CGIX key stats
Cancer Genetics Inc - CGIX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Cancer Genetics Inc as a
Sell with a ratings score of D.
Report Snippet: We rate CANCER GENETICS INC (CGIX) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, poor profit margins and generally disappointing historical performance in the stock itself.